Journal ArticleDOI
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Yaakov Dickstein,Jonathan Lellouche,Ma’ayan Amar,David A. Schwartz,Amir Nutman,Vered Daitch,Dafna Yahav,Dafna Yahav,Leonard Leibovici,Anna Skiada,Anastasia Antoniadou,George L. Daikos,Roberto Andini,Rosa Zampino,Emanuele Durante-Mangoni,Johan W. Mouton,Lena E. Friberg,Yael Dishon Benattar,Yael Dishon Benattar,Roni Bitterman,Ami Neuberger,Yehuda Carmeli,Yehuda Carmeli,Mical Paul,Mical Paul,Hiba Zayyad,Fidi Koppel,Yael Zak-Doron,Sergey Altunin,Nizar Andria,Anat Stern,Neta Petersiel,Marina Raines,Amir Karban,Noa Eliakim-Raz,Oren Zusman,Michal Elbaz,Heyam Atamna,Tanya Babich,Amos Adler,Inbar Levi,Ioannis Pavleas,Antigoni Kotsaki,Domenico Iossa,Mariano Bernardo,Giusi Cavezza,Lorenzo Bertolino,Giuseppe Giuffre,Roberto Giurazza,Susanna Cuccurullo,Maria Galdo,Patrizia Murino,Adriano Cristinziano,Antonio Corcione,Pia Clara Pafundi,Johan Mouton,Anders N. Kristoffersson,Ursula Theuretzbacher +57 more
Reads0
Chats0
TLDR
Colistin resistance as determined by BMD was associated with significantly lower mortality among patients with severe CRAB infections and colistin monotherapy wasassociated with a better outcome compared to colist in-meropenem combination therapy.Abstract:
Background We evaluated the association between mortality and colistin resistance in Acinetobacter baumannii infections and the interaction with antibiotic therapy. Methods This is a secondary anal ...read more
Citations
More filters
Journal ArticleDOI
The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How.
TL;DR: Novel drugs and combinations are not to be considered “panacea” for the ongoing crisis in the therapy of XDR Gram-negative bacteria and colistin will continue to been considered as a fundamental companion drug for the treatment of carbapenem-resistant Enterobacteriaceae, for thetreatment of CRPA (in many cases being the only in vitro active drug) as well as CRAB.
Journal ArticleDOI
Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints
Michael J. Satlin,James S. Lewis,Melvin P. Weinstein,Jean B. Patel,Romney M. Humphries,Gunnar Kahlmeter,Christian G. Giske,Christian G. Giske,John D. Turnidge +8 more
TL;DR: A viewpoint describes the opinions of the two organizations and the data that were used to inform their perspectives on polymyxins.
Journal ArticleDOI
Epidemiology of carbapenem-resistant Gram-negative infections globally
TL;DR: High-resistance rates in carbapenem-resistant GNB in many countries will inevitably complicate treatment of serious infections in vulnerable patient groups and should accelerate global attempts to overcome the impediments with regard to effective antimicrobial stewardship and infection prevention and control programs.
Journal ArticleDOI
Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)
Alexis Tabah,Matteo Bassetti,Marin H. Kollef,Jean-Ralph Zahar,José Artur Paiva,Jean-François Timsit,Jean-François Timsit,Jason A. Roberts,Jason A. Roberts,Jason A. Roberts,Jeroen Schouten,Helen Giamarellou,Jordi Rello,Jan J. De Waele,Andrew F. Shorr,Marc Leone,Garyphallia Poulakou,Pieter Depuydt,José Garnacho-Montero +18 more
TL;DR: A task force of 16 international experts was formed in November 2016 to provide with guidelines for clinical practice to develop questions targeted at defining ADE, its effects on the ICU population and to provide clinical guidance.
Journal ArticleDOI
Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study.
Alessandro Russo,Matteo Bassetti,Giancarlo Ceccarelli,Novella Carannante,Angela Raffaella Losito,Michele Bartoletti,Silvia Corcione,Guido Granata,Antonella Santoro,Daniele Roberto Giacobbe,Maddalena Peghin,Antonio Vena,Francesco Amadori,Francesco Vladimiro Segala,Maddalena Giannella,Giovanni Di Caprio,Francesco Menichetti,Valerio Del Bono,Cristina Mussini,Nicola Petrosillo,Francesco Giuseppe De Rosa,Pierluigi Viale,Mario Tumbarello,Carlo Tascini,Claudio Viscoli,Mario Venditti,Isgri-Sita +26 more
TL;DR: BSI caused by MDR-AB represents a difficult challenge for physicians, considering the high rates of septic shock and mortality associated with this infection.
References
More filters
Journal ArticleDOI
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes
TL;DR: Genotypic and phenotypic methods that provide relevant information for diagnostic laboratories are presented and recent works in relation to recently identified mechanisms of polymyxin resistance, including chromosomally encoded resistance traits as well as the recently identified plasmid-encoded polymyXin resistance determinant MCR-1 are presented.
Journal ArticleDOI
Acinetobacter baumannii: evolution of a global pathogen.
TL;DR: The recent expansion of A. baumannii sequenced genomes has permitted the development of large-array phylogenomic and phenotypic analyses, which can offer valuable insights into the evolution and adaptation of the human pathogen.
Journal ArticleDOI
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul,Mical Paul,George L. Daikos,Emanuele Durante-Mangoni,Dafna Yahav,Dafna Yahav,Yehuda Carmeli,Yehuda Carmeli,Yael Dishon Benattar,Yael Dishon Benattar,Anna Skiada,Roberto Andini,Noa Eliakim-Raz,Noa Eliakim-Raz,Amir Nutman,Amir Nutman,Oren Zusman,Oren Zusman,Anastasia Antoniadou,Pia Clara Pafundi,Amos Adler,Yaakov Dickstein,Ioannis Pavleas,Rosa Zampino,Vered Daitch,Vered Daitch,Roni Bitterman,Hiba Zayyad,Fidi Koppel,Inbar Levi,Tanya Babich,Tanya Babich,Lena E. Friberg,Johan W. Mouton,Ursula Theuretzbacher,Leonard Leibovici,Leonard Leibovici +36 more
TL;DR: Combination therapy was not superior to monotherapy and the addition of meropenem to colistin did not improve clinical failure in severe A baumannii infections.
Journal ArticleDOI
Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence
Matthew E. Falagas,Panagiota Lourida,Panagiotis Poulikakos,Petros I. Rafailidis,Giannoula S. Tansarli +4 more
TL;DR: Evaluating the effectiveness of the antibiotic treatment administered for infections caused by carbapenemase-producing Enterobacteriaceae found that combination antibiotic treatment may be considered the optimal option for severely ill patients with severe infections.
Journal ArticleDOI
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Zubair A. Qureshi,Lauren E. Hittle,Jessica A. O'Hara,Jesabel I. Rivera,Alveena Syed,Ryan K. Shields,Anthony W. Pasculle,Robert K. Ernst,Yohei Doi +8 more
TL;DR: Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colist in-susceptible, and -resistant isolates, suggesting evolution of resistance during CMS therapy.
Related Papers (5)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul,Mical Paul,George L. Daikos,Emanuele Durante-Mangoni,Dafna Yahav,Dafna Yahav,Yehuda Carmeli,Yehuda Carmeli,Yael Dishon Benattar,Yael Dishon Benattar,Anna Skiada,Roberto Andini,Noa Eliakim-Raz,Noa Eliakim-Raz,Amir Nutman,Amir Nutman,Oren Zusman,Oren Zusman,Anastasia Antoniadou,Pia Clara Pafundi,Amos Adler,Yaakov Dickstein,Ioannis Pavleas,Rosa Zampino,Vered Daitch,Vered Daitch,Roni Bitterman,Hiba Zayyad,Fidi Koppel,Inbar Levi,Tanya Babich,Tanya Babich,Lena E. Friberg,Johan W. Mouton,Ursula Theuretzbacher,Leonard Leibovici,Leonard Leibovici +36 more
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Brian T. Tsuji,Jason M. Pogue,Alexandre P. Zavascki,Mical Paul,Mical Paul,George L. Daikos,Alan Forrest,Daniele Roberto Giacobbe,Claudio Viscoli,Helen Giamarellou,Ilias Karaiskos,Donald Kaye,Johan W. Mouton,Vincent H. Tam,Visanu Thamlikitkul,Richard G. Wunderink,Jian Li,Roger L. Nation,Keith S Kaye +18 more
Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink,Evangelos J. Giamarellos-Bourboulis,Galia Rahav,Amy J. Mathers,Matteo Bassetti,Jose A. Vazquez,Oliver A. Cornely,Joseph S. Solomkin,Tanaya Bhowmick,Jihad Bishara,George L. Daikos,Timothy Felton,Maria Jose Lopez Furst,Eun J. Kwak,Francesco Menichetti,Ilana Oren,Elizabeth Alexander,David E. Griffith,Olga Lomovskaya,Jeffery Loutit,Shu Zhang,Michael N. Dudley,Keith S Kaye +22 more